Systemic vasculitis
(Redirected from Systemic vasculitides)
Overview of systemic vasculitis
Systemic vasculitis refers to a group of disorders characterized by inflammation of blood vessels, which can affect various organs and tissues throughout the body. This condition can lead to vessel wall damage, resulting in tissue ischemia and organ dysfunction.
Classification[edit | edit source]
Systemic vasculitis is classified based on the size of the affected blood vessels:
Large vessel vasculitis[edit | edit source]
Medium vessel vasculitis[edit | edit source]
Small vessel vasculitis[edit | edit source]
- Granulomatosis with polyangiitis
- Microscopic polyangiitis
- Eosinophilic granulomatosis with polyangiitis
Pathophysiology[edit | edit source]
The pathophysiology of systemic vasculitis involves immune-mediated inflammation of the blood vessel walls. This can be triggered by infections, drugs, or autoimmune processes. The inflammation leads to vessel wall damage, which can cause stenosis, aneurysm formation, or rupture.
Clinical manifestations[edit | edit source]
The clinical manifestations of systemic vasculitis vary depending on the size and location of the affected vessels. Common symptoms include:
- Fever
- Fatigue
- Weight loss
- Muscle and joint pain
Organ-specific symptoms[edit | edit source]
- Renal: Hematuria, proteinuria, renal failure
- Pulmonary: Cough, hemoptysis, dyspnea
- Dermatological: Purpura, ulcers, nodules
Diagnosis[edit | edit source]
Diagnosis of systemic vasculitis involves a combination of clinical evaluation, laboratory tests, and imaging studies. Common diagnostic tools include:
- Blood tests: Elevated inflammatory markers, ANCA
- Biopsy: Histological examination of affected tissue
- Imaging: Angiography, MRI, CT scan
Treatment[edit | edit source]
Treatment of systemic vasculitis aims to reduce inflammation and prevent organ damage. Common treatment options include:
- Corticosteroids: Prednisone
- Immunosuppressive drugs: Cyclophosphamide, methotrexate
- Biologic agents: Rituximab
Prognosis[edit | edit source]
The prognosis of systemic vasculitis depends on the type and severity of the disease, as well as the response to treatment. Early diagnosis and appropriate management are crucial for improving outcomes.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD